IL6 and neoplasm: Our findings indicate that a high level of IL-6 in MBC patients is associated with a pro-inflammatory tumor microenvironment, which promotes recruitment of MDSCs and suppresses anti-tumor immunity, including CD8+ lymphocyte activity.